Boai NKY Pharmaceuticals Ltd (300109) - Total Liabilities
Based on the latest financial reports, Boai NKY Pharmaceuticals Ltd (300109) has total liabilities worth CN¥552.11 Million CNY (≈ $80.79 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Boai NKY Pharmaceuticals Ltd cash flow conversion to assess how effectively this company generates cash.
Boai NKY Pharmaceuticals Ltd - Total Liabilities Trend (2007–2024)
This chart illustrates how Boai NKY Pharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. Check 300109 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Boai NKY Pharmaceuticals Ltd Competitors by Total Liabilities
The table below lists competitors of Boai NKY Pharmaceuticals Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenzhen Sunrise New Energy Co Ltd
SHE:002256
|
China | CN¥537.86 Million |
|
Develia S.A
WAR:DVL
|
Poland | zł3.24 Billion |
|
Beijing Sanyuan Foods Co Ltd
SHG:600429
|
China | CN¥3.98 Billion |
|
Anhui Shanying Paper Industry Co Ltd
SHG:600567
|
China | CN¥35.65 Billion |
|
Shanghai Chengdi Constr Co
SHG:603887
|
China | CN¥9.64 Billion |
|
Derichebourg
PA:DBG
|
France | €1.44 Billion |
|
Rami Levi
TA:RMLI
|
Israel | ILA4.00 Billion |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
|
USA | $12.54 Million |
Liability Composition Analysis (2007–2024)
This chart breaks down Boai NKY Pharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Boai NKY Pharmaceuticals Ltd market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Boai NKY Pharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Boai NKY Pharmaceuticals Ltd (2007–2024)
The table below shows the annual total liabilities of Boai NKY Pharmaceuticals Ltd from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥764.37 Million ≈ $111.85 Million |
+52.98% |
| 2023-12-31 | CN¥499.66 Million ≈ $73.12 Million |
-16.20% |
| 2022-12-31 | CN¥596.29 Million ≈ $87.26 Million |
+1.11% |
| 2021-12-31 | CN¥589.76 Million ≈ $86.30 Million |
-44.84% |
| 2020-12-31 | CN¥1.07 Billion ≈ $156.46 Million |
-6.54% |
| 2019-12-31 | CN¥1.14 Billion ≈ $167.42 Million |
+11.42% |
| 2018-12-31 | CN¥1.03 Billion ≈ $150.27 Million |
+56.48% |
| 2017-12-31 | CN¥656.22 Million ≈ $96.03 Million |
+687.58% |
| 2016-12-31 | CN¥83.32 Million ≈ $12.19 Million |
+13.97% |
| 2015-12-31 | CN¥73.11 Million ≈ $10.70 Million |
-1.71% |
| 2014-12-31 | CN¥74.38 Million ≈ $10.88 Million |
+63.18% |
| 2013-12-31 | CN¥45.58 Million ≈ $6.67 Million |
-0.51% |
| 2012-12-31 | CN¥45.81 Million ≈ $6.70 Million |
+18.06% |
| 2011-12-31 | CN¥38.80 Million ≈ $5.68 Million |
+57.75% |
| 2010-12-31 | CN¥24.60 Million ≈ $3.60 Million |
-49.45% |
| 2009-12-31 | CN¥48.66 Million ≈ $7.12 Million |
+2.40% |
| 2008-12-31 | CN¥47.52 Million ≈ $6.95 Million |
-2.70% |
| 2007-12-31 | CN¥48.84 Million ≈ $7.15 Million |
-- |
About Boai NKY Pharmaceuticals Ltd
Boai NKY Medical Holdings Ltd. engages in the fine chemical and precision medicine businesses in China and internationally. The company produces and sells polyvinyl pyrrolidone (PVP), Orarez, and in vitro diagnostic products, as well as invests in tumor drugs. It offers its products for pharmaceutical products, such as APIs and excipients; personal care products, including cosmetics, haircare, or… Read more